A Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Public ClinicalTrials.gov record NCT01611090. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Randomized, Double-blind, Placebo-controlled Phase 3 Study of Ibrutinib, a Bruton's Tyrosine Kinase (BTK) Inhibitor, in Combination With Bendamustine and Rituximab (BR) in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Study identification
- NCT ID
- NCT01611090
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Enrollment
- 578 participants
Conditions and interventions
Interventions
- Ibrutinib Drug
- Bendamustine hydrochloride Drug
- Rituximab Drug
- Placebo Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 18, 2012
- Primary completion
- Jan 22, 2019
- Completion
- Jan 22, 2019
- Last update posted
- Mar 2, 2020
2012 – 2019
United States locations
- U.S. sites
- 42
- U.S. states
- 29
- U.S. cities
- 42
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Birmingham | Alabama | — | — |
| Not listed | Phoenix | Arizona | — | — |
| Not listed | Berkeley | California | — | — |
| Not listed | Duarte | California | — | — |
| Not listed | Greenbrae | California | — | — |
| Not listed | Stamford | Connecticut | — | — |
| Not listed | Washington D.C. | District of Columbia | — | — |
| Not listed | Boca Raton | Florida | — | — |
| Not listed | Jacksonville | Florida | — | — |
| Not listed | Atlanta | Georgia | — | — |
| Not listed | Marietta | Georgia | — | — |
| Not listed | Chicago | Illinois | — | — |
| Not listed | Springfield | Illinois | — | — |
| Not listed | Fort Wayne | Indiana | — | — |
| Not listed | Goshen | Indiana | — | — |
| Not listed | Indianapolis | Indiana | — | — |
| Not listed | Iowa City | Iowa | — | — |
| Not listed | Westwood | Kansas | — | — |
| Not listed | Louisville | Kentucky | — | — |
| Not listed | Paducah | Kentucky | — | — |
| Not listed | Marrero | Louisiana | — | — |
| Not listed | Baltimore | Maryland | — | — |
| Not listed | Worcester | Massachusetts | — | — |
| Not listed | Ann Arbor | Michigan | — | — |
| Not listed | Battle Creek | Michigan | — | — |
| Not listed | Detroit | Michigan | — | — |
| Not listed | Lansing | Michigan | — | — |
| Not listed | St Louis | Missouri | — | — |
| Not listed | Lincoln | Nebraska | — | — |
| Not listed | Lebanon | New Hampshire | — | — |
| Not listed | Hackensack | New Jersey | — | — |
| Not listed | Albuquerque | New Mexico | — | — |
| Not listed | Dunkirk | New York | — | — |
| Not listed | Hawthorne | New York | — | — |
| Not listed | New York | New York | — | — |
| Not listed | Bismarck | North Dakota | — | — |
| Not listed | Cleveland | Ohio | — | — |
| Not listed | Portland | Oregon | — | — |
| Not listed | Charleston | South Carolina | — | — |
| Not listed | Sioux Falls | South Dakota | — | — |
| Not listed | Temple | Texas | — | — |
| Not listed | Morgantown | West Virginia | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 113 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01611090, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 2, 2020 · Synced Jul 24, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01611090 live on ClinicalTrials.gov.